Submission of the unaudited financial results for Quarter ended, 30th June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals reported a strong Q1 FY26 with revenue from operations surging to Rs. 256.47 lakhs, more than double the Rs. 112.39 lakhs posted in the same quarter last year. The company swung from a loss of Rs. 26.63 lakhs in Q1 FY25 to a profit after tax of Rs. 36.21 lakhs, translating to EPS of Rs. 0.79 versus a negative Rs. 0.58 earlier. Total expenses rose to Rs. 208.01 lakhs from Rs. 139.27 lakhs, with cost of materials and other expenses being the main drivers. The auditor (Pulindra Patel & Co.) issued a clean limited review report with no qualifications. The board also approved the 36th AGM notice for September 25, 2025 and related e-voting arrangements.
A clear turnaround quarter — strong revenue growth and a return to profit are positive for shareholders, though the absolute earnings base remains small. The clean auditor review and improving operating margins may support near-term sentiment, but the stock is a small-cap and past annual results showed losses, so sustainability of this performance is key to watch.